Pharmacological interventions according to actionable genomic alterations
At least one genetic aberration was detected in 11 patients (84.6%). Actionable mutations were discovered in 10 patients (76.9%), and the median number of actionable alterations in our cohort was 2.0 (range, 0–6). Seven patients (53.8%) had clinical trial candidates. However, no patients were able to receive biomarker-matched therapy according to their genomic alterations.